ReviewTropical medicine and health2026
Antimicrobial resistance in Noma control: a costly neglect within existing neglect.
Review in Tropical medicine and health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNoma is a severe gangrenous orofacial disease affecting malnourished children aged 2-6 years in extreme poverty, with 85-90% mortality if untreated. Recently classified as a Neglected Tropical Disease, it is managed mainly with empirical broad-spectrum antibiotics. Antimicrobial resistance (AMR) threatens to undermine treatment, yet AMR remains largely absent from Noma research and policy. This review examines AMR prevalence and drivers in Noma, identifies knowledge and policy gaps, and proposes recommendations.
methodsWe reviewed literature on Noma microbiology and documented AMR, plus WHO NTD and AMR policy documents. Community and health system factors and surveillance capacity in Noma-endemic regions, primarily Sub-Saharan Africa, were synthesized.
resultsNoma lesions show marked dysbiosis with frequent detection of Fusobacterium necrophorum, Prevotella spp., Staphylococcus aureus, Pseudomonas aeruginosa, and a novel "Treponema sp. A". A 25-year retrospective analysis found that >92% of patients presented late, requiring prolonged antibiotics. Direct AMR data are scarce. Case reports documented MDR-Escherichia coli in Afghanistan (2012), Vancomycin-resistant Enterococci in South Korea (2022), ESBL E. coli in Mali (2021), Serratia marcescens (Ticarcilline, amoxicillin, and sulfamethoxazole-trimethoprim) and Pseudomonas aeruginosa (Rifampicin) in Chad (2014); and Pseudomonas aeruginosa (penicillins, carbapenems, aminoglycosides, sulfamethoxazole-trimethoprim, and nitrofurantoin) in Italy (2015). A recent metagenomic study reported high β-lactam and metronidazole resistance determinants, especially in Prevotella spp. Drivers include empirical broad-spectrum antibiotic use, self-medication, irrational prescribing, and weak diagnostics, with only a small share of laboratories across 14 SSA countries performing routine bacteriology and susceptibility testing. Policy gaps persist: WHO NTD and AMR strategies are siloed, anaerobes are excluded from GLASS surveillance, and Noma guidelines lack AMR triggers.
conclusionAMR risks reversing gains in Noma control, and treatment centers may become AMR amplification sites without stewardship. Given limited microbiology data, we recommend adding AMR indicators to WHO and national Noma strategies, integrating anaerobic AMR surveillance at sentinel sites, generating Noma-specific antibiograms, and mandating antimicrobial stewardship in Noma programs. Mainstreaming AMR in Noma research and policy is essential to preserve therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.